PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers.
He Y, Li W, Zhang M, Wang H, Lin P, Yu Y, Huang B, Hao M, He J, Kong W, Luo D, Xu T, Wang J, Huang Y, Zhao Q, Liu Y, Zhang J, Nian Y, Zhang L, Zhu B, Yin C.
He Y, et al. Among authors: yu y.
J Exp Med. 2025 Mar 3;222(3):e20241147. doi: 10.1084/jem.20241147. Epub 2025 Jan 22.
J Exp Med. 2025.
PMID: 39841180